CNBX Pharmaceuticals Inc. 8-K

What Happened
CNBX Pharmaceuticals Inc. announced in an 8-K that on March 10, 2026 it executed a non-convertible Promissory Note with 3i L.P. for $45,000. The note bears simple interest at 5% per annum, is due July 1, 2026, and the proceeds will be used for immediate working capital and expenditures.

Key Details

• Lender: 3i L.P. (Delaware limited partnership).
• Principal: $45,000.
• Interest: 5% per annum, simple interest.
• Maturity: July 1, 2026 (note dated March 10, 2026).
• Note is non-convertible; proceeds earmarked for working capital and expenditures.

Why It Matters
This filing documents a short-term financing arrangement that provides immediate cash for operations. The amount is modest, the debt is non-dilutive (no conversion to equity), and it carries a fixed simple interest cost. Investors should note the near-term maturity (July 1, 2026), which affects CNBX’s short-term liquidity needs and repayment obligations.